PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia
Phase 1/2
≤0.536985860011622
4 sites in AR, NC, NV
About this study
This Phase 1/Phase 2 study is testing montelukast 4 mg granule in people with bronchopulmonary dysplasia bpd. The primary outcome being measured is Apparent clearance (CL/F) of montelukast.
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
leukotriene inhibitor (Leukotriene receptor antagonist; reduces inflammation in airways)
oral (Oral Tablet)
Primary: Apparent clearance (CL/F) of montelukast
Secondary: Area Under Curve (AUC), Half-life, Maximum Concentration (Cmax), Serious Adverse Events, Total Neuropsychiatric Adverse Events (NPAE)